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ABSTRACT 
 
A human in-vivo toxicokinetic model was built to allow a better understanding of the 
toxicokinetics of folpet fungicide and its key ring biomarkers of exposure: phthalimide (PI), 
phthalamic acid (PAA) and phthalic acid (PA). Both PI and the sum of ring-metabolites, 
expressed as PA equivalents (PAeq), may be used as biomarkers of exposure. The conceptual 
representation of the model was based on the analysis of the time course of these biomarkers 
in volunteers orally and dermally exposed to folpet. In the model, compartments were also 
used to represent the body burden of folpet and experimentally relevant PI, PAA and PA 
ring metabolites in blood and in key tissues as well as in excreta, hence urinary and faeces. 
The time evolution of these biomarkers in each compartment of the model was then 
mathematically described by a system of coupled differential equations. The mathematical 
parameters of the model were then determined from best-fits to the time courses of PI and 
PAeq in blood and urine of five volunteers administered orally 1 mg/kg and dermally 10 
mg/kg of folpet. In the case of oral administration, the mean elimination half-life of PI from 
blood (either through faeces, urine or metabolism) was found to be 39.9 h as compared to 
28.0 h for PAeq. In the case of a dermal application, mean elimination half-life of PI and PAeq 
was estimated to be 34.3 and 29.3 h, respectively. The average final fractions of administered 
dose recovered in urine as PI over the 0-96 h period were 0.030% and 0.002%, for oral and 
dermal exposure, respectively. Corresponding values for PAeq were 24.5% and 1.83%, 
respectively. Finally, the average clearance rate of PI from blood calculated from the oral 
and dermal data was 0.09 ± 0.03 mL/h and 0.13 ± 0.05 mL/h while the volume of distribution 
was 4.30 ± 1.12 L and 6.05 ± 2.22 L, respectively. It was not possible to obtain the 
corresponding values from PAeq data due to the lack of blood time course data.  
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Table of Contents – Short abstract 
A human in-vivo toxicokinetic model was built to allow a better understanding of the 
toxicokinetics of folpet fungicide and its key biomarkers of exposure, and to simulate the 
transformation of folpet into PI and other ring-metabolites:  phthalamic (PAA) and phthalic 
acids (PA). The model closely reproduced the time courses of PI in blood and urine as well 
as total ring-metabolites in urine of five volunteers administered orally 1 mg/kg and dermally 
10 mg/kg of folpet. 
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INTRODUCTION 
 
Folpet (CAS 133-07-3) is a fungicide commonly used in agricultural environments. It is 
applied for preventive treatment of plants to control mildew, gray mold, spoilage fungi and 
wood rot fungi. Folpet is a broad-spectrum contact protectant fungicide which denatures 
fungal proteins by reacting with their thiol groups (USEPA, 1999; Gordon, 2010). In 
humans, it is classified as probable human carcinogen (B2) by the US Environmental 
Protection Agency (1975, 1999) based on an increased incidence of duodenum tumors in 
mice chronically exposed to high doses by gavage. It is also considered as a severe irritant 
of the eyes, skin, nose and throat (Lisi et al.,1987; Guo et al.,1996; Gordon, 2010). 
 
Although folpet is widely used in agriculture, there is a paucity of data to assess the 
importance of exposure to this compound in workers (Zainal and Que, Hee 2003; Lebailly 
et al., 2006) and no biomonitoring data is available in literature to our knowledge. Moreover, 
the human toxicokinetics of folpet and its ring metabolites is not fully understood, although 
its knowledge is necessary to interpret biomonitoring data in field studies. 
 
The majority of toxicokinetic data on folpet was obtained from in vivo experiments in 
animals following radiolabelled-dosing as well as in vitro studies. These studies allowed the 
identification of the main metabolic pathway of folpet (Fig. 1). According to these studies, 
folpet is rapidly split at the N-S link when it is in contact with thiol groups and the reaction 
is enhanced in acid conditions (Gordon et al., 2001; Gordon, 2010). From this non-enzymatic 
process, the ring-metabolite PI and a thiocarbonyl chloride are formed. The initial ring-
metabolite of folpet, PI, is rapidly hydrolyzed to phthalamic acid (PAA) mainly and in turn 
to phthalic acid (PA), according to animal studies (Gordon et al., 2001; Zainal and Que Hee, 
2003; Canal-Raffin et al., 2008; Gordon, 2010). 
 
Following oral or intraperitonal administration of ring-labelled folpet, between 90 and 100% 
of dose were excreted in the urine of rats over a 24-h period post-dosing. This is based on 
the study of Wood et al. (1991) showing that 92% of an orally administered dose of 10 mg/kg 
of 14C-labelled folpet in rats were recovered in urine as 14C equivalents as compared to 6% 
in faeces. Couch et al. (1977) also indicated that virtually 100% of an intraperitoneal dose 
of 6 mg/kg of 14C-folpet were recovered in urine as 14C equivalents and 1.7% in faeces over 
the 24-h period post-dosing. 
 
When PI metabolite was orally administered to rats, about 80% of the administered dose 
were metabolized and excreted in urine as PAA, 7% were found as PA, and less than 1% of 
the dose was recovered as PI in urine (Chasseaud et al., 1974). PAA also represented the 
main metabolite (i.e. 80%) when labeled 14C-folpet was orally administered to rats 
(Chasseaud, 1980). However, they reported that this metabolite was unstable in urine. The 
rat studies of Chasseaud et al. (1974, 1980) thus showed that PAA and PA appear as 
quantitatively more important biomarkers than PI. Nonetheless, PA is not a metabolite 
4 
 
specific to folpet; it is also a derivative of phthalates, which are ubiquitous molecules in our 
environment (Blount et al., 2000; Silva et al., 2007). 
 
Furthermore, in the only dermal penetration study on folpet in animals, Shah et al. (1987) 
estimated a low dermal absorption fraction, as assessed from analysis of radioactivity in skin 
and carcasses at 72 h post-application of a low, medium and high dose of 14C-trichloromethyl 
labelled folpet in Fisher 344 rats as well as in urine and faeces collected over the 72-h period 
post-dosing. On average, 12% of the low dose of folpet were calculated to be absorbed 
through the skin during that time (application of 0.1 µmol/cm2 on 2.8 and 5.6 cm2 of young 
and adult rats, respectively) as compared to only 3 and 1% for the two higher doses 
(application of 0.5 and 2.7 µmol/cm2, respectively). 
 
With regard to elimination kinetics of PI, Canal-Raffin et al. (2008) reported an elimination 
half-life of on average 2.5 h in plasma following a single intraperitoneal folpet dose of 10 
mg/kg in Wistar rats. Ackermann et al. (1978) also estimated a PI half-life of 2 h in rat 
fetuses following an oral administration of 2.5 mg/kg of 15N-phthalimide to pregnant Wistar-
strain albino rats and observed a fast metabolism of PI into PAA. This latter metabolite is 
then transformed to PA, the final ring-metabolite of folpet (Williams and Blanchfield, 1974). 
On the other hand, in an in vitro study, Gordon et al. (2001) reported a half-life of labelled-
folpet added to human blood of 4.9 seconds. 
 
Recently, the human time courses of PI in blood and urine of volunteers orally and dermally 
exposed to folpet were documented (Berthet et al., 2011a,b). The objective of the present 
study was to use these new data to develop a biomathematical model to describe and better 
understand the toxicokinetics of folpet and its ring metabolites in humans. No such model 
has been developed so far to describe the toxicokinetics of folpet in humans.   
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MATERIALS AND METHODS 
 
Data used for folpet model development 
 
Model development was based on available published metabolism data (Gordon et al., 2001) 
along with the human time-course data newly collected in volunteers (Berthet et al., 
2011a,b). In this controlled experiment of Berthet et al. (2011a,b), healthy volunteers were 
exposed orally to 1 mg/kg of folpet or dermally to 10 mg/kg of folpet. The detailed time 
courses of PI in plasma and in urine were determined during a 96-h period post-dosing. Only 
urine time courses for PAeq were documented during a 96-h period post-dosing.  
 
Conceptual and functional representation of folpet model 
 
The kinetics of PI and of PAeq were modeled separately. Conceptual representations are 
depicted in Fig. 2 and Fig. 3. Symbols and abbreviations are defined in Table 1. The 
mathematical implementation of the models as systems of first-order differential equations 
is given in Table 2. In the modeling, it was considered that absorbed folpet is almost 
instantaneously broken down into its ring- and thiol-metabolites, leading respectively to PI 
and TTCA metabolites. However, only the pathway leading to the formation of the PI and 
PAeq biomarkers of exposure was modeled in the current work.  
 
The kinetics of folpet and its ring-metabolites (monitored PI and the sum of ring-metabolites, 
PAeq) were modeled for different routes-of-exposure: oral, dermal and inhalation. The input 
doses per unit of time, bioavailable at each site of absorption, the skin, the respiratory tract 
and the GI tract, were thus respectively described as gdermal(t), ginh(t) and goral(t). To simulate 
oral exposure, the model considers compartments for folpet in the GI (GFT(t)) and for the 
almost instantaneously generated PI (GPI) and ring-metabolites of PI (GPAA and GPA). 
Compartments were also used to represent the body burden of experimentally relevant PI, 
PAA and PA ring metabolites in blood and in tissues in dynamical equilibrium with blood, 
i.e. tissues that rapidly reach and maintain a fixed ratio with blood (referred to later as the 
blood compartment BPI(t), BPAA(t) and BPA(t), respectively, for simplicity). Other non-
monitored ring-metabolites (BON(t)) were also represented as body compartments. Similarly, 
different excretion compartments were introduced to represent the amounts of PI, PAA and 
PA metabolites in urine and faeces, that is urinary compartments UPI(t), UPAA(t) and UPA(t), 
or faecal compartments FPI(t), FPAA(t) and FPA(t); other excretion compartments were added 
to describe the non-monitored ring-metabolites in urine (UON(t)) as well as in faeces (FON(t)).  
 
To simulate the kinetics of PI specifically, PAA and PA compartments were grouped 
whereas to simulate the kinetics of PAeq, PI, PAA and PA compartments were lumped. The 
compartments proposed for body metabolites and for excretion are based on the published 
data and appear sufficient in number to capture, for quantitative assessments, the essential 
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features of the kinetics of the measured metabolites. The linear elimination of PI from blood 
observed in Berthet et al. (2011a) suggests the absence of a significant storage of folpet in 
the body, either as an accumulation in lipids or a binding to tissue proteins, and indicates 
that the whole body distribution of folpet ring-metabolites can be described using a single 
compartment B(t) with first order elimination. 
 
To simulate the kinetics of PI specifically in blood and urine following dermal absorption, 
the epidermis and the dermis were represented as separate compartments (SEFT(t) and 
SDPI(t), respectively). On the other hand, when simulating the kinetics of PAeq, only the 
epidermal compartment was represented (SEFT(t)) given the absence of measured blood time 
course of PAeq, which simplifies model representation. Thus, all the specific features related 
to the modeling of dermal kinetics of PI specifically were shadowed by the important 
amounts of PAA and PA produced at the site-of-entry and contributing to total PAeq.  
 
On the contrary, simulations showed that it was not necessary to add a respiratory tract 
compartment as an input since the rapid absorption of folpet through the respiratory tract can 
be viewed kinetically as an almost constant intravenous exposure; thus, inhalation exposures 
were modeled by direct inputs to the blood compartment and instant fragmentation at the N-
S link. This route-of-exposure was represented simply to show that it can be accounted for 
in the model. However, there is no available experimental data to date on the time course of 
ring biomarkers following inhalation exposure to folpet. To insure conservation of mass, all 
amounts were initially expressed on a mole basis to run the model. 
 
Once the model was functionally represented by systems of differential equations (see Table 
2), solving these equations yielded the mathematical functions for the time courses of folpet 
and each of its relevant metabolites in the different compartments. Initial conditions for every 
compartment were set to be zero at starting time of the kinetic modeling.  
 
Determination of folpet model parameters 
 
Model parameters were then determined by best-fit adjustments of the analytical solutions 
of differential equations to the data of Berthet et al. (2011a,b) on the time courses of PI in 
plasma and PI and PAeq urine of volunteers orally and dermally exposed to folpet. MathCad 
14 software was used for this purpose (PTC (Parametric Technology Corporation), 
Needham, MA, USA). 
 
Several procedures exist to best-fit general analytical functions to data sets. For fitting, the 
algorithm genfit (included in Mathcad) was used, which essentially reproduces a least square 
minimization. To simplify differential equations and allow a first estimate of parameter 
values, use was made of the different time scales during which the various biological 
processes occur (e.g., time of absorption, distribution, metabolism, and excretion). Usually, 
in time, any exposure biomarker of interest finds its way to the final elimination site but on 
different time scales. The exact body location of a particular metabolite in time will depend 
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on the relative time scales of biological processes. Considering these time scales, in many 
cases, analytical solutions simplify to single exponential functions. For example, following 
a single oral exposure, the function describing blood time course of PI (BPI(t)) will 
completely be driven by the overall rate of elimination of PI from blood (defined by kB) and 
will be independent of the oral absorption dynamics (described by the overall disappearance 
rate of PI from the GI, kG). In this case, kB<<kG, such that the blood time course of PI (BPI(t)) 
reduces to: 
 BPI(t) kB≪kG�⎯⎯⎯� kGBDkG e−kBt.       (1) 
 
Similarly, inhaled folpet is promptly absorbed into blood (in the order of min) such that the 
rate of appearance of PI in urine will only be limited by the overall elimination rate of PI 
from blood.  
 
Moreover, when comparing oral and dermal rate time courses of PI, it was observed that 
elimination slopes were similar. The parallelism indicates that the final elimination phase of 
PI following dermal exposure is not governed by skin absorption rate (neither the rate of 
epidermal diffusion of folpet (kSESD) or the diffusion rate of PI almost instantaneously 
formed in the dermis (kSDB)) but is rather driven by the overall elimination rate of PI from 
blood, kB, as in the case of oral administration. The same holds true for PAeq.  
 
When looking at the data of Berthet et al. (2011a,b) on the elimination rate of PI in blood 
and urine as a function of time considering a given route of exposure (oral or dermal), it was 
also shown that elimination slopes were similar for blood and urine, as expected. Therefore, 
the transfer rate of PI from blood to urine, kBU, can straightforwardly be computed directly 
from each of the observed blood and urinary time courses of Berthet et al. (2011a,b) as 
follows: 
 kBU = UPI(t)
∫ dt′BPI(t′)t0 .         (2) 
 
In other words, for a given route of administration, experimental ratios of cumulative urinary 
excretion of PI to the area under the curve of blood PI is equal to a constant, defined as kBU 
(UPI(t)/AUC BPI(t) ~ kBU), and thus follow a quasi-constant trend in time. This is the 
behaviour required by our first-order model. Otherwise, the rates of elimination would not 
be a simple constant but would rather depend on the amounts of PI present in each 
compartment.  
 
With regard to the oral route and overall disappearance rate of PI from the GI, represented 
by kG, it is dependent not only on the absorption of PI from the GI tract into blood (kGB), but 
also on the direct elimination of PI in faeces (without absorption) (kGF) and GI metabolism 
of PI to other ring-metabolites (kGO). The transfer rate kGB of PI from the GI to blood can be 
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defined as a proportion fb of the overall disappearance rate of PI from the GI (kG). The 
transfer rates kGB, kGO and kGF can in turn easily be defined as follows: 
 kGB = fbkG,          (3) kGF + kGO = (1− fb)kG.        (4) 
 
On the other hand, the dermal analogues to these parameters, the rate of epidermal diffusion 
of folpet (kSESD), the diffusion rate of PI almost instantaneously formed in the dermis (kSDB) 
and the dermal absorption fraction (fabs), can be calculated in the same manner. For PAeq 
parameters, a strategy similar to the one used to determine the parameters related to the 
kinetics of PI specifically can be used. With all the effective transfer rate parameters fixed, 
the model is completed and ready for sensitivity analysis.  
 
Sensitivity analysis of folpet model parameters  
 
There are several tests to measure the sensitivity of a particular parameter on a given 
function. Sensitivity analysis is the mathematical procedure aiming at assessing how much 
the value of a dependent function is modified as one changes a particular independent degree 
of freedom, while keeping all the remaining parameters unaffected. One can measure this 
effect by means of the normalized sensitivity coefficient defined as: 
 
σs(β) = βδ f(β+δ)-f(β)f(β) .         (5) 
 
This coefficient measures changes in model simulations defined by f with respect to the 
change δ of the parameter β under assessment. If the sensitivity coefficient is zero, the kinetic 
model is independent of the given parameter. If the coefficient diverges to infinity, 
simulation is highly sensitive to the model parameter and, therefore, the mathematical model 
is unstable. In our case, we have allowed all the degrees of freedom to vary a conservative 
standard deviation around the mean experimental data.      
 
With this range of variability, the sensitivity coefficient for every degree of freedom in our 
model was calculated. This coefficient was computed for every single experimental time 
point and average values were then calculated.  
 
Model evaluation  
 
The model developed using the data of Berthet et al. (2011a,b) was evaluated using two 
independent sets of experimental data, namely plasma and urine time course data following 
both oral and dermal exposure. The kinetics of two different biomarkers was also modeled, 
namely PI specifically and PAeq, hence allowing to verify the consistency between both 
mathematical simulations independently. 
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RESULTS 
 
Development of folpet model and simulations of experimental kinetic data 
 
Table 3 presents average parameter values of the model. Figure 4 shows that the model 
reproduces closely the data of Berthet et al. (2011a) on the average time courses of PI in 
blood and urine of volunteers exposed orally to folpet (R2 of 0.663 and 0.989, respectively). 
With the same parameters, the model also simulated well the dermal data provided by 
Berthet et al. (2011b) on the average blood and urinary time courses of PI in volunteers (R2 
of 0.573 and 0. 976, respectively) (Fig. 5) as well as PAeq values in urine (Fig. 6)  (R2=0.973 
for oral and R2=0.988 for dermal). 
 
The good correspondence of our mathematical model with experimental data, using 
parameter values presented in Table 3, has corroborated our principal hypotheses about 
folpet kinetics, namely: a) it is almost instantaneous broken down to PI and its counterpart 
thiol metabolite at the site-of-entry (GI following oral exposure and dermis following dermal 
application); b) folpet ring-metabolites are rapidly absorbed into blood and then readily 
eliminated from the body following both oral and dermal exposures; c) the skin dermis does 
not retain folpet ring-metabolites, as the dermal absorption rate was found to be larger than 
the overall elimination rate of metabolites from blood; d) folpet is not stored in body 
compartments; e) PI is a specific biomarker of folpet exposure but is only a minor metabolite; 
f) the kinetics of PI is similar to that of total ring metabolites, expressed as PAeq, but the 
latter is a much more abundant biomarker, although less specific to folpet. 
 
Overall elimination half-life of PI from blood was found to be 39.9 h following oral exposure 
as compared to 34.3 h following dermal application. By comparison, the overall elimination 
half-life of PAeq was found to be 28.0 h following oral administration as compared to 29.3 h 
after dermal application. These values indicate a fairly rapid tissue distribution, 
biotransformation and elimination of both PI and PAeq, with values in the same range for 
both biomarkers (PI and PAeq) and both routes-of-entry (oral and dermal). According to the 
model, four different processes contribute to total elimination rate of PI specifically from 
blood: biotransformation to other ring-metabolites, faecal excretion, renal clearance and 
finally distribution to non-observed organs. Of all the preceding mechanisms, renal clearance 
contributes mainly to the overall elimination rate of PI from blood (85.5%) following oral 
administration. On the other hand, following dermal application, renal clearance contributed 
only to 27.0% of PI overall elimination from blood, the remaining being attributed to 
metabolism of PI into derivatives or faecal excretion of blood PI.  
 
When modeling the kinetics of total ring-metabolites, it was not possible to extract the exact 
contribution of the renal and faecal clearance to the overall elimination rate of PAeq from the 
blood compartment, because only the time course of PAeq in urine was experimentally 
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available (not blood). However, following oral exposure in volunteers, considering that the 
elimination of PAeq in urine is almost complete 96 h post-exposure, it can roughly be 
estimated with the model that 24.5% of ingested folpet is eliminated as PAeq in urine while 
the remaining 75.5% should either be eliminated as PAeq in faeces or be found as 
unaccounted metabolites. Similarly, with the model, 7.42% of folpet were predicted to be 
absorbed through the skin, with 24.7% of absorbed amounts being excreted as PAeq in urine 
and 75.3% as PAeq in faeces or as unaccounted metabolites in the body. 
 
From the time course curves of PI in blood, other calculated parameters include the discrete 
version of the area under the concentration-time curve (AUC), the area under the first 
moment of concentration–time curve (AUMC), the clearance from blood (CL), the apparent 
volume of distribution (Vd) and the mean residence time (MRT) as presented in Table 4. 
When looking at the predicted blood time course of PI (described by the analytical function 
BPI(t)), maximum level for an oral exposure was obtained at around 4 h (and representing 
0.0325% of ingested dose according to simulations as compared to 0.0397% of dose 
experimentally observed). This is simply due to competing rates of oral absorption and 
elimination of PI from the blood compartment. By comparison, following dermal 
application, this concomitant impact of absorption and elimination rates causes the blood 
profile to present a maximum level of PI at around 10 h. After dermal exposure, maximum 
level was lower than after ingestion (representing 0.00697% of applied dose according to 
simulations as compared to 0.0123% of dose experimentally observed), due to the small 
dermal absorption fraction, and time to maximum level is slightly delayed by the transfer 
rate through the skin. 
 
Furthermore, it is interesting to note that the time course of PI in blood was parallel to that 
of PI urinary excretion rate, for both oral and dermal exposures, which indicates that the 
kinetics of PI is well described by considering solely the compartments BPI(t) and UPI(t). For 
example, in the oral model, if there were some crucial phenomenon occurring in the kidney, 
the blood and urinary time profiles would not necessarily evolve in parallel. Moreover, a 
single exponential elimination was apparent from slopes of the time course curves of PI in 
blood. This is an important indicator of the absence of any kind accumulation of PI in the 
body, which would then be reflected by at least a bi-exponential decrease rather than a mono-
exponential elimination.  
 
Regarding biotransformation of PI into its derivatives more specifically, it was taken to occur 
at the site-of-entry (GI or dermis following oral and dermal exposure, respectively) or as 
soon as PI reaches systemic blood. Given that PI is simulated to be largely metabolized to 
derivatives in the GI tract, the fraction of PI itself absorbed from the GI into blood is found 
to be very small (0.0353%). As for the importance of metabolism of PI to other ring-
metabolites in blood, it could not be determined precisely for lack of faecal time course data. 
Therefore, only the concomitant contribution of metabolism of PI to derivatives and faecal 
excretion to the overall elimination of PI from the blood compartment could be computed, 
namely, 14.5% for oral exposure and 73.0% for dermal application (with the rest 
corresponding to renal clearance of PI). 
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In the particular case of model simulation of skin absorption and ensuing dermal kinetics of 
PI, separate skin sub-compartments had to be described. The first segment (SEFT for folpet) 
is the one that effectively represents the dynamics of the absorption of folpet through the 
epidermis. By definition, the first segment describes the passive diffusion of unchanged 
folpet. The effective rate of diffusion of folpet was found to be KSESD= 2.22×10-1 h-1. The 
second segment (SDPI for PI) simply represents the dermis which is irrigated by blood and 
therefore allows for the folpet to instantaneously biotransform into PI. Thus, this 
compartment accounts for the formation of PI and its rate of transfer from skin to blood with 
a half-life of 51.5 min. To model the toxicokinetics of PAeq and not just PI specifically 
following dermal exposure, the toxicokinetic parameters describing skin absorption of folpet 
(absorption fraction and absorption rate) were taken to be the same as the ones calculated 
from the blood time course curves of PI; therefore, the dermal absorption fraction was set to 
be 0.0742 and the dermal absorption rate of folpet was taken to be kSESD =2.22×10-1 h-1. 
Interestingly, when comparing this value with the overall rate of appearance of PI in blood 
following oral exposure (kG, otherwise defined as the rate of disappearance from the GI), 
which is calculated to be 1.06 h-1, dermal absorption rate appears quite rapid. 
 
 
Sensitivity analysis of model parameters 
 
Sensitivity coefficients were computed for every single experimental time point and average 
values were calculated as reported in Table 5. The most sensitive parameters were those 
expected to shift the simulations by simple y-axis translation (the oral absorption fraction fb, 
the dermal absorption fraction fabs and the rate of elimination of PI or PAeq from blood to 
urine kBU and k’’BU), while the shape of the curves were mostly sensitive to changes in the 
slope defined by the overall elimination rate of PI or PAeq from blood, kB or k’’B, the overall 
disappearance rate of PI or PAeq from the GI after oral exposure, kG and k’’G, and the dermal 
absorption rate kSESD. With respect to kSDB, the analysis also showed an important effect of 
its variation on the time course curves. Due to the fact that folpet is rapidly absorbed, any 
variation in the transfer rates from the epidermis to dermis and/or variation in the metabolism 
at the site-of-entry will result in a phenomenon similar to a time delay or a translation on the 
time-axis.  
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DISCUSSION 
 
This study allowed a better understanding of the kinetics of PI, PAeq as potential key 
biomarkers of exposure to folpet. It enabled to relate an internal dose of folpet to the time 
courses of PI and PAeq biomarkers in available biological fluids (such as blood and urine). 
Effective compartment models, with two mathematical components, were built to represent 
the kinetics of those biomarkers. The toxicokinetic models provided a very good 
approximation of the experimental time course data of Berthet et al. (2011a,b) in volunteers 
orally and dermally exposed to folpet under controlled conditions. 
 
According to model simulations and in line with Gordon (2010), the first biological process 
governing the kinetics of folpet is its almost instantaneous non-enzymatic breakdown into 
PI and thiophosgene. PI biotransformation into PA and PAA at the sites-of-entry (GI for oral 
exposure and dermis for dermal exposure) was also found to be relatively rapid. Once in 
blood, PI elimination was found to be fairly rapid (kB=31.6 h) and was modeled to occur 
through metabolism to PAA and PA, renal clearance and fecal excretion. On the other hand, 
when simulating the time course of PAeq, which accounts for total ring-metabolites, 
elimination from blood was dependent only on renal and biliary clearance. Levels of PI and 
PAeq in non monitored tissues (such as liver, kidney or lung) were taken to rapidly reach a 
dynamical equilibrium with blood and were theoretically assumed to evolve in parallel. PI 
and PAeq in blood and these tissues were thus lumped under a single compartment defined 
as PI or PAeq blood compartment for simplicity. 
 
The excellent agreement between model simulations and measured blood and urinary time 
course data following an oral and dermal exposure in volunteers, considering a single-
exponential model for PI and PAeq elimination from blood and tissues in dynamical 
equilibrium with blood, also confirmed the lack of significant storage of the parent 
compound or the metabolites in any tissue components (e.g. adipose tissues, protein binding 
as well as other body lipid components). This is in line with animal studies showing 
negligible accumulation of phthalimide moieties (Couch et al., 1977; Ackermann et al., 
1978) in tissues following oral or intraperitoneal administration of labelled folpet. 
 
In the particular case of model simulation of an oral exposure in humans, a single GI 
compartment was introduced to describe site-of-entry kinetics of PI and PAeq and account 
for GI metabolism, absorption in blood as well as the intestinal transit time which delays 
appearance of PI and PAeq in faeces (in the latter case with a half-life of 39.1 min for PI 
specifically and of 31 min for PAeq). Following folpet ingestion in humans, even though it 
is almost instantaneously broken down into PI in the GI, only a very small fraction of PI 
reaches blood (0.0353% according to the model). This result can be a priori be understood 
as an efficient elimination of folpet and/or PI directly through faeces without being absorbed. 
However, experimental data in rats show that following oral or intraperitonal administration 
of ring-labelled folpet, between 90 and 100% of the administered dose were excreted in the 
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urine of rats over a 24-h period post-dosing (Wood et al., 1991; Couch et al., 1977). 
Therefore, the small amounts of PI transferred to blood following ingestion of folpet can 
only be explained by a rapid biotransformation of PI into PAA and PA in the GI, the latter 
of which are subsequently readily absorbed into systemic blood. 
 
It is also noteworthy that the mathematical model did not require consideration of an 
enterohepatic recycling of any ring metabolite, as no feedback features were apparent from 
the available blood time course data in volunteers (Berthet et al., 2011a,b). Therefore, 
contribution of this process to the overall excretion dynamics was found negligible and thus 
had no impact on the kinetics of distribution and elimination of these metabolites. 
 
On the other hand, to simulate dermal exposure, PI in the skin was represented by two sub-
compartments. As previously mentioned, the first segment simply represents passive 
diffusion of folpet through the epidermis (3.13 h) while the second accounts for the actual 
formation, metabolism and dynamics of PI in the dermis with a half-life of 51.5 min. The 
latter time scales show the rapid skin absorption when exposed to folpet in humans. While 
folpet dermally absorbed is quickly metabolized at the site-of-entry and readily distributed 
to the systemic blood compartment, only a small fraction of applied folpet penetrates the 
skin barrier (7.42% according to the model). This is in agreement with the rat data from the 
only dermal penetration study on folpet in animals, showing a low dermal absorption fraction 
(Shah et al., 1987). With respect to model simulation of PAeq kinetics following dermal 
exposure, the toxicokinetic parameters describing skin absorption of folpet (absorption 
fraction and absorption rate) were taken to be the same as the ones calculated from the blood 
time course curves of PI. 
 
Once applied folpet reaches the dermis, which is irrigated by blood, it was modeled to be 
almost instantaneously metabolized to PI. This is supported by the available in vitro data of 
Gordon et al. (2001) showing that the half life of 14C-labelled folpet (1 mg/L) added to 
human blood was estimated to be in the order of second (4.9 s). In the model, PI is in turn 
mostly metabolized to PAA and PA at the site-of-entry. The PI reaching the blood 
compartment is predicted to be eliminated in large part by renal clearance (representing 
88.5% of overall elimination according to the model) while the rest (11.5%) represents PI 
metabolism and fecal excretion. Most plausibly, faecal excretion is very limited according 
to animal data (Couch et al., 1977). Unfortunately, even if our toxicokinetic model accounted 
for these processes, the experimental data available in humans did not include faecal matrix. 
 
With respect to renal clearance more specifically, the parallelism observed between the 
blood and the urine compartments is clear evidence that the kidney is in complete kinetic 
equilibrium with blood and that no particular retention mechanism occurs for PI in the 
kidney. Furthermore, according to model simulations, no saturation in absorption, 
distribution, metabolism of PI or urinary excretion was apparent at the 1 mg/kg oral and 10 
mg/kg dermal doses administered to subjects.  
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CONCLUSION 
 
This study succeeded in developing a toxicokinetic model for PI and the sum of ring 
metabolites PI, PAA and PA, which provided a close match to a large set of experimental 
time course data in two biological matrices of exposed volunteers. This modeling provided 
new insights into the mechanistic determinants of folpet kinetics that can serve for a better 
understanding and use of ring-metabolites as proper biomarkers.  
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Table 1. Symbols used in the functional representation of the model 
Model 
parameter Units Description 
GFT(t) mol Amounts of folpet in the GI as a function of time 
GPI(t) mol Amounts of PI in the GI as a function of time 
GPAA(t) mol Amounts of PAA in the GI as a function of time 
GPA(t) mol Amounts of PA in the GI as a function of time 
SEFT(t) mol Amounts of folpet in the epidermis as a function of time 
SDPI(t) mol Amounts of PI in the dermis as a function of time 
SDPAA(t) mol Amounts of PAA in the dermis as a function of time 
SDPA(t) mol Amounts of PA in the dermis as a function of time 
BPI(t) mol Burden of PI in the blood compartment as a function of time 
BPAA(t) mol Burden of PAA in the blood compartment as a function of time 
BPA(t) mol Burden of PA in the blood compartment as a function of time 
BON(t) mol Burden of non-monitored ring-metabolites in the blood compartment as a function of time 
FPI(t) mol Amounts of PI excreted in faeces as a function of time 
FPAA(t) mol Amounts of PAA excreted in faeces as a function of time 
FPA(t) mol Amounts of PA excreted in faeces as a function of time 
FON(t) mol Amounts of non-monitored ring-metabolites in faeces as a function of time 
UPI(t) mol Amounts of PI excreted in urine as a function of time 
UPAA(t) mol Amounts of PAA excreted in urine as a function of time 
UPA(t) mol Amounts of PA excreted in urine as a function of time 
UON(t) mol Amounts of non-monitored ring-metabolites excreted in urine as a function of time 
kGB h-1 Rate of PI absorption from the GI into the blood compartment 
kGF h-1 Rate of faecal elimination of unabsorbed PI (directly from the GI) 
kGO h-1 Rate of PI biotransformation to other non-monitored ring-metabolites in the GI 
kG h-1 Rate of overall disappearance of PI from the GI either through absorption 
in blood, metabolism to other ring-metabolites or excretion in faeces 
(kGB+kGO+ kGF) 
k’’GB h-1 Rate of total ring-metabolites (sum of PI, PAA and PA expressed as PAeq) 
absorption from the GI into the blood compartment 
k’’GF h-1 Rate of faecal elimination of unabsorbed total ring-metabolites (sum of PI, 
PAA and PA expressed as PAeq) (directly from the GI) 
k’’G h-1 Rate of overall disappearance of total ring-metabolites (sum of PI, PAA 
and PA expressed as PAeq) from the GI either through absorption in blood. 
or excretion in faeces (k’’GB+ k’’GF) 
kBB h-1 Rate of PI biotransformation to other non-monitored ring-metabolites in the body 
kBU h-1 Transfer rate of PI from blood to urine 
kBF h-1 Transfer rate of PI from blood to faeces 
kB h-1 Overall elimination rate of PI from the blood compartment (kBU+kBF+ kBB) 
k’’BU h-1 Transfer rate of total ring-metabolites (sum of PI, PAA and PA expressed 
as PAeq) from blood to urine 
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Model 
parameter Units Description 
k’’BF h-1 Transfer rate of total ring-metabolites (sum of PI, PAA and PA expressed 
as PAeq) from blood to faeces 
k’’B h-1 Overall elimination rate of total ring-metabolites (sum of PI, PAA and PA 
expressed as PAeq) from the blood compartment (k’’BU+k’’BF) 
kSESD  h-1 Rate of epidermal diffusion of folpet 
kSDB h-1 Rate of diffusion of ring-metabolites in the dermis where they are almost 
instantaneously formed 
kSDO h-1 Rate of PI biotransformation to other non-monitored ring-metabolites in the dermis 
fabs 
fb 
fu 
 
Dermal absorption fraction of folpet 
Proportion of PI in the GI, which is transferred to blood 
Proportion of blood PI excreted in urine 
D(t) mg/kg Absorbed dose as a function of time 
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Table 2. First-order linear differential equations describing the kinetics of folpet and its PI, 
and PAeq metabolites in each of the model compartments 
Exposure 
route Compartment 
Differential equations 
PI kinetics PAeq=PI+PAA+PA kineticsa 
Oral Gastrointestinal 
tract 
dGPI(t)dt = Dδ(t)− kGGPI(t) dGPAeq(t)dt = Dδ(t)− k′′GGPAeq(t) 
 
Blood 
compartment 
dBPI(t)dt = kGBGPI(t)− kBBPI(t) dBPAeq(t)dt = k′′GBGPAeq(t)− k′′BBPAeq(t) 
 Urine dUPI(t)dt = kBUBPI(t) dUPAeq(t)dt = k′′BUBPAeq(t) 
 
Faeces dFPI(t)dt = kBFBPI(t) + kGFGPI(t) dFPAeq(t)dt = k′′BFBPAeq(t)+ k′′GFGPAeq(t) 
Dermal 
Epidermis 
dSEFT(t)dt = fabsDδ(t)
− kSESDSETI(t) dSPAeq(t)dt = fabsDδ(t)
− kSESDSPAeq(t)  
Dermis 
dSDPI(t)dt = kSESDSEFT(t)
− kSDBSDPI(t) 
 
Blood 
compartment 
dBPI(t)dt = kSDBSDPI(t)
− kBBPI(t) dBPAeq(t)dt = kSESDSPAeq(t)− k′′BBPAeq(t) 
 Urine dUPI(t)dt = kBUBPI(t) dUPAeq(t)dt = k′′BUBPAeq(t) 
 Faeces dFPI(t)dt = kBFBPI(t) dFPAeq(t)dt = k′′BFBPAeq(t) 
a The total amounts of ring metabolites, expressed as PAeq are defined as follows: GPAeq(t) =GPI(t) + GPAA(t) + GPA(t), BPAeq(t) = BPI(t) + BPAA(t) + BPA(t), SPAeq(t) = SPI(t) +SPAA(t) + SPA(t), UPAeq(t) = UPI(t) + UPAA(t) + UPA(t) and FPAeq(t) = FPI(t) + FPAA(t) +FPA(t). 
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Table 3. Model parameter values determined from the average blood and urinary time 
course data of Berthet et al. (2011a,b) in volunteers orally and dermally exposed to folpet 
 Model parametersa Values 
PI kinetics Transfer rates (h-1) kB 2.19×10-2 
  kBU 1.24×10-2 
  kG 1.06 
  kGB 3.75×10-4 
  kGF+ kGO 1.06 
  kSESD 2.22×10-1 
  kSDB+ kSDO 8.08×10-1 
  kSDB 1.01×10-3 
  kSDO 8.07×10-1 
 Fractional partition (%)  fb  3.53×10-2 
  fu  85.5 
  fabs  7.42 
    
PAeq kinetics a Transfer rates (h-1) k’’B 2.42×10-2 
  k’’BU 2.39×10-2 
  k’’G 1.39 
  k’’GB 1.37 
  k’’GF 1.39×10-2 
  kSESD 2.22×10-1 
 Fractional partition (%) f’’b  99.0 
  fu’’  99.0 
  fabs 7.42 
 
a Symbols and abbreviations used in this study are defined in Table 1.  
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Table 4. Toxicokinetic parameters derived from the average data of Berthet et al. (2011a,b) 
on the blood profile of PI following oral administration of 1 mg/kg of folpet or dermal 
application of 10 mg/kg 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Toxicokinetic parameters were calculated from the mean percentage of the dose profile.  
b The discrete version of the area under the curve is calculated as: AUC =
1
2
∑ (ti-ti+1)∀i [C(ti) + C(ti+1)]. 
c The first moment of concentration-time curve is approximated by: AUMC =
1
2
∑ (ti-ti+1)∀i [tiC(ti) + ti+1C(ti+1)]. 
d The clearance of the blood module was determined by: CL = Dose
AUC
. 
e The volume of distribution computed by: Vd = CLβ . 
f The mean residence time is defined as: MRT = AUMC
AUC
. 
  
 First-order toxicokinetic values for PI 
 Oral Dermal 
Model parameters a   
AUC b [µmol hr/L] 0.918 1.69 
AUMC c [µmol hr2/L] 26.9 35.4 
CL d [L/hr] 0.0944 0.133 
Vd e [L] 4.30 6.05 
MRT f [hr] 29.4 22.9 
 23 
 
Table 5. Sensitivity coefficients of model parameters with variability range 
Model parameters Urinary average sensitivity coefficient  
Blood average sensitivity 
coefficient 
  +δ -δ +δ -δ 
kB (oral) -0.255 0.311 -0.355 0.472 
kB (dermal) -0.234 0.284 -0.301 0.397 
fb, fabs and kBU (oral and 
dermal) 1.00 -1.00 1.00 -1.00 
kG (oral) 0.0596 -0.0954 0.0162 -0.0381 
kSESD (dermal) 0.233 -0.343 0.239 -0.335 
kSDB (dermal) 0.909 -0.909 0.888 -0.888 
 
 
  
 
Captions to Figures 
 
Figure 1. Metabolic pathway of folpet according to available in vivo experiments in 
animals and in vitro studies. 
 
Figure 2. Model conceptual representation of the kinetics of folpet with focus on PI and its 
ring-metabolites. Symbols and abbreviations are described in Table 1. 
 
Figure 3. Model conceptual representation of the kinetics of folpet and its PAeq ring-
metabolites. Symbols and abbreviations are described in Table 1. 
 
Figure 4. Model simulations (solid line) compared with experimental data of Berthet et al. 
(2011a) on A) the time course of PI in blood (% of dose) and B) the cumulative urinary 
excretion time courses of PI (% of dose) in five volunteers following an oral administration 
of 1 mg/kg bw of folpet (solid circles). Symbols represent average experimental values and 
vertical bars the experimental standard deviation (n = 5). 
 
Figure 5. Model simulations (solid line) compared with experimental data of Berthet et al. 
(2011b) on A) the time course of PI in blood (% of dose) and B) the cumulative urinary 
excretion time courses of PI (% of dose) in five volunteers following a dermal application 
of 10 mg/kg bw of folpet (solid circles). Symbols represent average experimental values 
and vertical bars the experimental standard deviation (n = 5). 
 
Figure 6. Model simulations (solid line) compared with experimental data of Berthet et al. 
(2011b) on the cumulative urinary excretion time course of PAeq (% of dose) in five 
volunteers following A) an oral ingestion of 1 mg/kg bw of folpet and B) a dermal 
application of 10 mg/kg bw of folpet (solid circles). Symbols represent average 
experimental values and vertical bars the experimental standard deviation (n = 5). 
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